Market for Multiple Myeloma Therapeutics in the US to Reach $4.0 Billion by 2015, According to New Report by Global Industry Analysts

Share Article

Driven by the rising incidences of multiple myeloma, approvals of new generation drugs like Revlimid®, promising drugs in pipeline, rising drug prices, steady utilization of maintenance therapy, and prolonged treatment cycles, the market for multiple myeloma therapeutics in the United States is forecast to reach $4.0 billion by the year 2015.

Multiple Myeloma Therapeutics: A US Market Report

Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been especially strong. Unfazed research and development activities, have over the years, resulted in commendable advances in treatment therapies and procedures. Drugs that are expected to be launched in the coming years include - Doxil, Perifisone, ZIO-101, and Tanespimycin. These would be used in combination with any of the three major drugs - Revlimid, Velcade, and Thalomid. Although patients today have a broader choice of treatments than before, the objective of all the treatment therapies is to slower the growth of malignant myeloma cells rather than elimination, and offer palliative care such as, reduction in disease symptoms, such as, fatigue, anemia, bone pain, and recurrent infections, among others.

Until lately, multiple myeloma therapeutics, and treatment regimes were dominated by generic oncology drugs, and lower priced branded drugs. The recent approval, and commercialization of new generation, expensive drugs have helped push value sales, and conversely the market into the bulge market. Velcade and Thalomid extended the much required revenue boost, while premium priced Revlimid, the most expensive among comparable counterparts, extended the final impetus required to push the market out of its orbit. With newer classes of costly, sophisticated drugs expected to be innovated, approved and commercialized in the upcoming years, the market is expected to continue on its upward trajectory in the medium to long-term.

Several factors underpinning growth in the market is expected to intensify and strengthen further. Noteworthy among these are increase in patient bases in all the lines of therapy including front line, first line, second line and third lines of treatment, rising drug prices, and steady utilization of maintenance therapy. With multiple myeloma being an incurable condition, and with the disease estimated to eventually progress in virtually all afflicted individuals, all patients are expected to be treated with all the available drugs, and combinations in all lines of therapy during their treatment period before death. Additionally, prolonged treatment cycles, and mandatory administration of maintenance therapy even during periods of remission, offer a strong platform for growth in the market.

Sales of the drug Revlimid in the United States is forecast to grow at the fastest CAGR over the years 2006 through 2015, as stated by the recent report published by Global Industry Analysts Inc. Thalomid, the hitherto gold standard in multiple myeloma treatment is expected to witness market erosion, as the use of the drug, elbowed aside by Revlimid, and Velcade, moves over to the third line treatment. This is primarily because of the number of undesirable side effects associated with the drug.

Key players dominating the market include Amgen Inc, Avalon Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kosan Biosciences Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech Inc., Genta Incorporated, Millennium Pharmaceuticals, Ortho Biotech Products LP, Seattle Genetics, and Ziopharm Oncology Inc.

The report titled "Multiple Myeloma Therapeutics: A US Market Report" published by Global Industry Analysts Inc., provides a comprehensive review of industry overview, drugs in pipeline, treatment regimes, market trends, issues and drivers, product overview, profiles of major players, and recent industry activity. The study quantifies latent demand potential for key drugs including Thalomid, Revlimid, and Velcade, among others. Quantitative analysis is also provided for lines of treatment, including, Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates, and Therapy for Relapsed or Refractory Myeloma.    

For more details about this research report, please visit

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website